Why Biogen Is Paying $5.6B to Buy Apellis Pharma

Дата публикации: 03-04-2026 14:00:00

CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions.Continue reading

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis	0	5	08-04-2026
2	Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug	5	7	07-04-2026
3	Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma	0	5	09-03-2026
4	American Pacific Group Invests in Dossier	0	5	03-04-2026
5	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion	0	7	06-07-2026
6	Pfizer приобретает Seagen за $43 млрд	0	0	13-03-2023
7	Digital Health Startups Raised $4B in Q1: How Cash Is Flowing Amid Uncertainty	0	5	07-04-2026
8	General Electric продаст свой бизнес в сфере биофармацевтики компании Danaher	0	0	25-02-2019
9	Taxation With Representation: Sidley, Paul Weiss, Kirkland	0	5	26-06-2026
10	Why Quantum Health Acquired Virtual Care Company CirrusMD	0	5	09-03-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: dealbreaker.com.